Advertisement

The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease

  • Sarah M. Jabour
  • Sara Beachy
  • Shayna Coburn
  • Sophie Lanzkron
  • Michelle N. EakinEmail author
Article
  • 24 Downloads

Abstract

Objective

This qualitative study analyzed the perspective of patients living with sickle cell disease (SCD) on their process of deciding whether to take hydroxyurea (HU), and the role of physician communication in patients’ decision-making process.

Methods

From October 2015 to July 2016, we conducted semi-structured interviews among patients with SCD (N = 20) that were audio-recorded and transcribed. Participants were ≥ 18 years old, a patient of an urban adult sickle cell center, able to provide informed consent, and English-speaking. We iteratively developed codes and used thematic analysis to organize the key themes.

Results

Most participants were female (65%), middle aged (M = 44, SD = 12.2), and 55% were prescribed HU for an average of 10.4 (SD = 4.7) years. Participants described 3 key factors that influenced their decision regarding HU treatment: (1) lifestyle, (2) health status, and (3) HU characteristics. Four themes emerged about provider communication and HU treatment decisions: (1) provider’s advisement, (2) shared decision-making, (3) “wrestled,” and (4) not feeling heard.

Conclusion

Providers who engaged in shared decision–making empowered participants to decide whether to start HU treatment. Participants who felt their providers were not listening to their concerns expressed disengaging from HU treatment. During discussions about HU with patients living with SCD, providers must understand the multi-faceted aspects that impact patients’ decision and empower patients to engage in such discussions. Further research is needed to understand the role of shared decision-making among patients with SCD to improve management of SCD.

Keywords

Sickle cell disease Patient-provider communication Shared decision-making, hydroxyurea 

Notes

Acknowledgments

We wish to thank the participants who participated in this study. We thank Yetunde Olagbaju for her help organizing the data collection. We thank Dr. Anne K. Monroe for her support.

Funding

This work received financial support from the National Heart, Lung, and Blood Institute R34 113438.

Compliance with Ethical Standards

Informed Consent and Patient Details Statement

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee (Johns Hopkins Institutional Review Board: IRB00073658) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

40615_2019_625_MOESM1_ESM.docx (87 kb)
ESM 1 (DOCX 87 kb)

References

  1. 1.
    Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. Am J Hematol. 2002;70:206–15.CrossRefPubMedGoogle Scholar
  2. 2.
    Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2010;85:77–8.PubMedGoogle Scholar
  3. 3.
    Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38:S512–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention. Complications and treatment of sickle cell disease. 2017. https://www.cdc.gov/ncbddd/sicklecell/treatments.html. Accessed 16 May 2019.
  5. 5.
    Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, et al. National institutes of health consensus development conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148:932–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2017;64:e26369.CrossRefGoogle Scholar
  8. 8.
    Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006;4:59.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Thornburg CD, Calatroni A, Panepinto JA. Differences in health related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol. 2011;33:251–4.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Haywood C Jr, Beach MC, Lanzkron S, Strouse JJ, Wilson R, Park H, et al. A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J Natl Med Assoc. 2009;101:1022–33.CrossRefPubMedGoogle Scholar
  11. 11.
    National Heart, Lung, and Blood Institute. The management of sickle cell disease. NIH publication. 2002;55.Google Scholar
  12. 12.
    Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol. 2010;3:255–60.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lanzkron S, Haywood C Jr, Segal JB, Dover GJ. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol. 2006;81:927–32.CrossRefPubMedGoogle Scholar
  14. 14.
    Lanzkron S, Haywood C Jr, Hassell KL, Rand CS. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the sickle cell disease adult provider network. J Natl Med Assoc. 2008;100:968–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Ritho J, Liu H, Hartzema AG, Lottenberg R. Hydroxyurea use in patients with sickle cell disease in a Medicaid population. Am J Hematol. 2011;86:888–90.CrossRefPubMedGoogle Scholar
  16. 16.
    Stettler N, McKiernan CM, Melin CQ, Adejoro OO, Walczak NB. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. JAMA. 2015;313:1671–2.CrossRefPubMedGoogle Scholar
  17. 17.
    Elmariah H, Garrett ME, De Castro LM, Jonassaint JC, Ataga KI, Eckman JR, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89:530–5.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI. Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health Qual Life Outcomes. 2017;15:136.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Badawy SM, Thompson AA, Penedo FJ, Lai JS, Rychlik K, Liem RI. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol. 2017;98:608–14.CrossRefPubMedGoogle Scholar
  20. 20.
    Candrilli SD, O’Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011;86(3):273–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Zumberg MS, Reddy S, Boyette RL, Schwartz RJ, Konrad TR, Lottenberg R. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. Am J Hematol. 2005;79:107–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Badawy SM, Thompson AA, Liem RI. Beliefs about hydroxyurea in youth with sickle cell disease. Hematol Oncol Stem Cell Ther. 2018;11(3):142–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Haywood C Jr, Beach MC, Bediako S, Carroll CP, Lattimer L, Jarrett D, et al. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol. 2011;86:85–7.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Barbour RS. Checklists for improving rigour in qualitative research: a case of the tail wagging the dog? BMJ. 2011;322:1115–7.CrossRefGoogle Scholar
  25. 25.
    Levitt HM, Motulsky SL, Wertz FJ, Morrow SL, Ponterotto JG. Recommendations for designing and reviewing qualitative research in psychology: promoting methodological integrity. Qual Psychol. 2017;4:2–22.CrossRefGoogle Scholar
  26. 26.
    Patton M. Qualitative evaluation and research methods, vol. 3. Sage; 2002.Google Scholar
  27. 27.
    Sullivan GM, Sargeant J. Qualities of qualitative research: part I. J Grad Med Educ. 2011;4:449–52.CrossRefGoogle Scholar
  28. 28.
    Sinha CB, Bakshi N, Ross D, Krishnamurti L. From trust to skepticism: an in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. PLoS One. 2018;13:e0199375.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Crosby LE, Shook LM, Ware RE, Brinkman WB. Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia. Pediatr Blood Cancer. 2015;62:184–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Crosby LE, Walton A, Shook LM, Ware RE, Treadwell M, Saving KL, et al. Development of a hydroxyurea decision aid for parents of children with sickle cell anemia. J Pediatr Hematol Oncol. 2019;41:56–63.CrossRefPubMedGoogle Scholar
  31. 31.
    Ross D, Bakshi N, Khemani K, Sinha C, Loewenstein G, Krishnamurti L. What are the expectations of patients in decision making process of disease modifying therapies for sickle cell disease: do they care about shared decision making? Blood. 2016;128:5968.Google Scholar
  32. 32.
    Elander J, Beach MC, Haywood C Jr. Respect, trust, and the management of sickle cell disease pain in hospital: comparative analysis of concern-raising behaviors, preliminary model, and agenda for international collaborative research to inform practice. Ethn Health. 2011;16:405–21.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Haywood C Jr, Bediako S, Lanzkron S, Diener-West M, Strouse J, Haythornthwaite J, et al. An unequal burden: poor patient–provider communication and sickle cell disease. Patient Educ Couns. 2014;96:159–64.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Haywood C Jr, Diener-West M, Strouse J, Carroll CP, Bediako S, Lanzkron S, et al. Perceived discrimination in health care is associated with a greater burden of pain in sickle cell disease. J Pain Symptom Manag. 2014;48:934–43.CrossRefGoogle Scholar
  35. 35.
    Haywood C Jr, Williams-Reade J, Rushton C, Beach MC, Geller G. Improving clinician attitudes of respect and trust for persons with sickle cell disease. Hosp Pediatr. 2015;5:377–84.CrossRefPubMedGoogle Scholar
  36. 36.
    Haywood C Jr, Lanzkron S, Ratanawongsa N, Bediako SM, Lattimer-Nelson L, Beach MC. Hospital self-discharge among adults with sickle-cell disease (SCD): associations with trust and interpersonal experiences with care. J Hosp Med. 2010;5:289–94.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Haywood C Jr, Lanzkron S, Ratanawongsa N, Bediako SM, Lattimer L, Powe NR, et al. The association of provider communication with trust among adults with sickle cell disease. J Gen Intern Med. 2010;25:543–8.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Haywood C Jr, Lanzkron S, Bediako S, Strouse JJ, Haythornthwaite J, Carroll CP, et al. Perceived discrimination, patient trust, and adherence to medical recommendations among persons with sickle cell disease. J Gen Intern Med. 2014;29:1657–62.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Stanton MV, Jonassaint CR, Bartholomew FB, Edwards C, Richman L, DeCastro L, et al. The association of optimism and perceived discrimination with health care utilization in adults with sickle cell disease. J Natl Med Assoc. 2010;102:1056–63.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Badawy SM, Cronin RM, Hankins J, Crosby L, DeBaun M, Thompson AA, et al. Patient-centered eHealth interventions for children, adolescents, and adults with sickle cell disease: systematic review. JMIR. 2018;20:e10940.PubMedGoogle Scholar
  41. 41.
    Badawy SM, Thompson AA, Liem RI. Technology access and smartphone app preferences for medication adherence in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2016;63:848–52.CrossRefPubMedGoogle Scholar
  42. 42.
    Crosby LE, Ware RE, Goldstein A, Walton A, Joffe NE, Vogel C, et al. Development and evaluation of iManage: a self-management app co-designed by adolescents with sickle cell disease. Pediatr Blood Cancer. 2017;64:139–45.CrossRefPubMedGoogle Scholar
  43. 43.
    Jonassaint CR, Shah N, Jonassaint J, De Castro L. Usability and feasibility of an mHealth intervention for monitoring and managing pain symptoms in sickle cell disease: the Sickle Cell Disease Mobile Application to Record Symptoms via Technology (SMART). Hemoglobin. 2015;39:162–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Shah N, Jonassaint J, De Castro L. Patients welcome the sickle cell disease mobile application to record symptoms via technology (SMART). Hemoglobin. 2014;38:99–103.CrossRefPubMedGoogle Scholar
  45. 45.
    Utrankar A, Mayo-Gamble TL, Allen W, Novak L, Kassim AA, Bonnet K, et al. Technology use and preferences to support clinical practice guideline awareness and adherence in individuals with sickle cell disease. J Am Med Inform Assoc. 2018;25:976–88.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© W. Montague Cobb-NMA Health Institute 2019

Authors and Affiliations

  • Sarah M. Jabour
    • 1
  • Sara Beachy
    • 2
  • Shayna Coburn
    • 3
    • 4
  • Sophie Lanzkron
    • 5
  • Michelle N. Eakin
    • 6
    Email author
  1. 1.Division of General Internal MedicineJohns Hopkins UniversityBaltimoreUSA
  2. 2.Department of Education and Health ServicesLehigh UniversityBethlehemUSA
  3. 3.Children’s National Health SystemWashington, D.C.USA
  4. 4.The George Washington UniversityWashington, D.C.USA
  5. 5.Division of HematologyJohns Hopkins UniversityBaltimoreUSA
  6. 6.Division of Pulmonary and Critical Care MedicineJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations